May issue editorial by Thierry Heles, editor, Global University Venturing
Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.
The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.
March issue editorial by editor Thierry Heles.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.
Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.
February 2019 issue editorial by editor Thierry Heles